Modra Pharmaceuticals is a leading pharmaceutical brand that specializes in developing oral taxane therapies. With a commitment to transforming taxane therapy, Modra aims to create better options for cancer patients and improve their quality of life. The brand's proprietary boosted taxane approach enhances the delivery, bioavailability, and tolerability of taxanes, resulting in fewer side effects.

Modra's pipeline of clinical-stage proprietary boosted oral taxanes is designed to replace the commonly used intravenous docetaxel and paclitaxel. By offering novel oral therapies that can be taken at home, Modra seeks to revolutionize the cancer treatment experience. Their lead program, ModraDoc006/r, is specifically developed to enhance the efficacy, safety, and tolerability of docetaxel therapy.

With a focus on patient benefit, Modra Pharmaceuticals is dedicated to addressing the limitations of current taxane treatments and improving the lives of cancer patients worldwide. Contact Modra Pharmaceuticals for more information about their innovative therapies and transformative approach to cancer treatment